Bionomics Shareholders Approve Scheme of Arrangement for Re-Domiciliation

Bionomics Limited (OTCMKTS:BNOEF) has achieved a significant milestone as shareholders voted to approve the proposed Scheme of Arrangement, enabling the company’s re-domiciliation from Australia to the United States. The decision, made at a special meeting on December 11, 2024, reflects a transformative step for the Australian corporation.

The Scheme of Arrangement involves a strategic move for Bionomics, where Neuphoria Therapeutics Inc., a Delaware corporation, will become the new parent company of Bionomics Limited upon completion. Shareholders demonstrated their support for the scheme, with an overwhelming majority voting in favor of the re-domiciliation.

Voting results indicated robust support for the Scheme among Bionomics shareholders:
– 96% of the votes cast favored the Scheme.
– 87% of shareholders present and voting supported the re-domiciliation, whether in person, through proxy, attorney, or corporate representative.

The next steps for Bionomics include fulfilling customary conditions outlined in the Scheme Implementation Agreement. These conditions include approval from the Supreme Court of New South Wales, affirmation by an independent expert of the Scheme’s benefit to shareholders, and satisfying any pending conditions before the Second Court Hearing scheduled for December 16, 2024.

Upon meeting the remaining conditions, the Scheme’s implementation is anticipated to finalize around December 24, 2024. Following this completion, shares of the new entity, Neuphoria, are expected to commence trading on Nasdaq under the symbol “NEUP” on the same day or shortly thereafter.

The re-domiciliation signifies a strategic realignment for Bionomics Limited, embracing opportunities in the United States market. The move positions the company for potential growth and operational advantages in its new landscape.

For additional information or queries, interested parties are encouraged to reach out to:
– Rajeev Chandra, Company Secretary, at [email protected]
– Investor Relations contacts: Kevin Gardner at [email protected] and Chris Calabrese at [email protected]

About Bionomics Limited:
Bionomics Limited is a clinical-stage biotechnology company focused on developing novel allosteric ion channel modulators, primarily targeting central nervous system disorders with substantial unmet medical needs. The company’s lead drug candidate, BNC210, shows promise in treating conditions such as Social Anxiety Disorder and Post-Traumatic Stress Disorder.

Cautionary Statement:
Bionomics advises that forward-looking statements in this press release are based on current beliefs and expectations, with actual results subject to inherent business risks. The company urges investors not to place undue reliance on such statements and highlights the importance of understanding the risks associated with its operations.

The press release does not constitute an offer to sell securities within any jurisdiction, emphasizing that the Neuphoria shares have specific regulatory considerations restricting their sale.

This news reflects Bionomics Limited’s commitment to transparency, shareholder engagement, and strategic growth as it progresses through its re-domiciliation process.

This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read Bionomics’s 8K filing here.

About Bionomics

Bionomics Limited, a clinical stage biopharmaceutical company, discovers and develops novel drug candidates for the treatment of central nervous system disorders and cancers. The company's lead drug candidate includes BNC210, a negative allosteric modulator of the a7 nicotinic acetylcholine receptor, which is in phase 2 clinical trial for the treatment of social anxiety disorder and phase 2b to treat post-traumatic stress disorder.